Mirum Published Results of Livmarli (maralixibat) for the Treatment of Alagille Syndrome in Hepatology
Shots:
- The company highlighted the results from the clinical studies evaluating Livmarli in patients with ALGS
- The results from the retrospective analysis showed an improvement in pruritus from baseline to 48wk. was predictive of 6yr. EFS & TFS (88% vs 57% & 93% vs 57%) over patients with minimal to no improvement in pruritus; serum bile acids of <200μmol/L (85% vs 49% & 90% vs 49%); 50% reduction in sBA (86% vs 39% & 90% vs 39%), 48wk. bilirubin <6.5mg/dL (90% vs 43% & 94% vs 42%)
- The overall predictive ability of these variables was stable over several years with all 3 variables being correlated. Livmarli, an ileal bile acid transporter inhibitor was approved in the US for cholestatic pruritus in patients with ALGS aged ≥3mos. & in the EU in patients aged ≥2mos.
Ref: Businesswire | Image: Mirum
Related News:- Mirum Submits Application to the EMA for Marketing Authorization of Livmarli for Progressive Familial Intrahepatic Cholestasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
